Guest Editor:
Prof. Dr. Ricard Cervera
Department of Autoimmune Diseases, Institut Clinic of Medicine and Dermatology, Hospital Clinic, Villarroel, 170, 08036 Barcelona, Catalonia, Spain
RCERVERA@clinic.cat

Deadline for manuscript submissions: closed (31 December 2016)

Message from the Guest Editor
Dear Colleagues,

Antiphospholipid syndrome (APS) is an autoimmune disorder caused by antiphospholipid antibodies. It was characterized by excessive clotting of blood and/or certain complications of pregnancy (premature miscarriages, unexplained fetal death, or premature birth) and the presence of antiphospholipid antibodies (such as anti-cardiolipin antibodies or lupus anticoagulant) in the blood. Fifty percent of people with lupus have APS. The exact pathogenesis of APS is inadequately understood, so no specific treatment is available.

This Special Issue of Antibodies focuses on the symptoms, pathogenesis, diagnosis, clinical manifestation, therapy of APS, the new research development of antiphospholipid antibodies, and all the other aspects of APS.

Prof. Dr. Ricard Cervera
Guest Editor

Author Benefits
Open Access: free for readers, with publishing fees paid by authors or their institutions.
High visibility: Indexed in the Emerging Sources Citation Index (ESCI - Web of Science), EMBASE (Elsevier) and other databases.
Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 57 days after submission; acceptance to publication is undertaken in 12 days (median values for papers published in this journal in 2016).